Skip to main content

Lupus


Browse the latest news, expert commentary, and educational content on lupus.


Highlights

Close up of medical disposable syringe and vial

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

Close up young woman taking pill, holding water glass

01-11-2022 | Systemic lupus erythematosus | News

Dapagliflozin may warrant further investigation for SLE

Dapagliflozin deserves further study as an add-on therapy for reducing renal and cardiovascular risk in patients with systemic lupus erythematosus, suggest preliminary trial findings.

Clogged Artery, Arteriosclerosis Cholesterol plaque. 3d illustration

01-09-2022 | Cardiovascular disease | News

CV risk reduction should be ‘an integral part’ of autoimmune disease management

A large study published in The Lancet has found that people with autoimmune diseases have an approximately 1.4–3.6-fold increased risk for developing cardiovascular disease relative to the general population.

More on lupus

19-12-2022 | Systemic lupus erythematosus | News

Anti-dsDNA antibodies have potential to guide targeted therapy use in SLE

An exploratory analysis of data from the phase 2b BEAT LUPUS trial suggests that IgA2 anti-dsDNA antibody levels may be able to predict response to B cell-targeted therapies in patients with systemic lupus erythematosus.

14-11-2022 | ACR 2022 | Conference coverage | News

Phase 3 trial supports add-on telitacicept for SLE

Addition of the recombinant fusion protein telitacicept to standard care may reduce disease activity and is well tolerated in people with systemic lupus erythematosus, research suggests.

10-11-2022 | Systemic lupus erythematosus | News

Achieving LLDAS tied to reduced mortality risk in SLE

Achievement of LLDAS is associated with a significant reduction in mortality risk among people with systemic lupus erythematosus, study findings suggest.

Keep up with podcasts on this topic, available on

Stay informed with Medicine Matters

Get the latest developments in rheumatology delivered straight to your inbox